Biotech giant Regeneron Pharmaceuticals, Inc. REGN is slated to report first-quarter 2025 results on April 29, 2025. The Zacks Consensus Estimate for revenues is pegged at $3.25 billion, while the ...

New manufacturing and supply agreement with FUJIFILM Diosynth Biotechnologies in North Carolina will enable additional production of Regeneron's biologic medicines and support high-paying jobs in ...

Sanofi and Regeneron’s trial compared Libtayo, a PD-1 inhibitor to platinum doublet chemotherapy in patients with first-line locally advanced or metastatic non-small cell lung cancer (NSCLC ...

The U.S. Food and Drug Administration (FDA) has approved Dupixent® (dupilumab) for treating adults and adolescents aged 12 and older with chronic spontaneous urticaria (CSU) who continue to ...

In the U.S., there are more than 300,000 adults and adolescents aged 12 years and older living with CSU who remain symptomatic despite antihistamine treatment TARRYTOWN, N.Y. and PARIS, April 18 ...

TARRYTOWN, N.Y. and PARIS, April 18, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that the U.S. Food and Drug Administration (FDA) has ...

Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier ...

checkpoint inhibitor as well as which patients with NSCLC would benefit from Regeneron's Libtayo (cemiplimab). "With the current European indication expansion of PD-L1 IHC 22C3 PharmDx into gastric or ...

New research shows that Medicaid expansion was linked to a 2.1% increase in timely lung cancer surgeries and a 2.8% rise in procedures at high-volume hospitals, highlighting how policy changes can ...

Although I do believe the oncology portfolio still needs a few years to mature, this segment is approaching an inflection point, as Libtayo continues to report growth and the company’s ...

A new study suggests that targeting the protein alpha-synuclein could be a possible new target for treating melanoma. Researchers have uncovered a surprising mechanism linking Parkinson’s disease and ...